Kymera Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
KYMR Nasdaq 2830 www.kymeratx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Kymera Therapeutics, Inc.

Kymera Therapeutics (KYMR) Upgraded to Buy: Here's Why - Jan 12th, 2026 10:00 am
Is Kymera Therapeutics (KYMR) Balancing Pipeline Ambition and Execution Risk After New KT-621 Milestone? - Jan 7th, 2026 11:11 am
Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 - Jan 6th, 2026 5:00 am
KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026? - Jan 5th, 2026 11:45 am
Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks - Jan 1st, 2026 9:35 am
The Biggest IPO of the Year Prompts Huge Insider Buy - Dec 30th, 2025 6:45 am
Share Offerings Prompt Huge Insider Buying in These 3 Biotechs - Dec 17th, 2025 7:45 am
Why Analysts See Kymera Therapeutics Differently After KT 621 Momentum And Rising Fair Value - Dec 16th, 2025 11:07 pm
Kymera Poised to Become Leading Firm in Multiple Inflammation & Immunology Indications, RBC Says - Dec 16th, 2025 9:57 am
Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. - Dec 14th, 2025 1:30 am
Kymera's Eczema Drug Gets Fast Track Designation in the United States - Dec 12th, 2025 8:30 am
Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - Dec 11th, 2025 2:01 pm
Kymera Therapeutics (KYMR) Valuation After KT-621 Fast Track Win and Strong Phase 1b BroADen Trial Data - Dec 11th, 2025 11:09 am
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis - Dec 11th, 2025 5:00 am
Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering - Dec 9th, 2025 9:30 pm
Kymera (KYMR) Jumps to All-Time High as Eczema Treatment Results Impress - Dec 9th, 2025 12:23 pm
KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study - Dec 9th, 2025 8:43 am
Kymera Rockets, Pulling Nurix Higher. Does It Have The Next Dupixent? - Dec 8th, 2025 2:07 pm
Kymera Therapeutics Announces Proposed Public Offering - Dec 8th, 2025 2:01 pm
This Drugmaker's Stock Is Soaring Over 40% Monday - Dec 8th, 2025 1:10 pm